As of Nov 19, 2026, 1 of 2 active firms rate PLRX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PLRX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.40
Range $-0.40 – $-0.40 · 1 analysts · +25% YoY
Next period, 1 analysts expect Pliant Therapeutics Inc to earn $-0.40 a share (range $-0.40 – $-0.40), versus $-0.32 a year earlier. Full-year consensus is $-1.44, growing to $-1.29 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Pliant Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PLRX.
#1
Brian Cheng
JP Morgan · Rank #87
Sell
No targeton PLRX
Overall win rate
51%
+ Follow
#2
EN
Edward Nash
Canaccord Genuity · Rank #270
Neutral
$3.00+357.9% to target
Overall win rate
44%
+ Follow
#3
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #300
Neutral
No targeton PLRX
Overall win rate
35%
+ Follow
#4
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$3.00+357.9% to target
Overall win rate
30%
+ Follow
#5
Brian Abrahams
RBC Capital · Rank #502
Neutral
$2.00+205.3% to target
Overall win rate
26%
+ Follow
PLRX stock forecast FAQ
What is PLRX's average 12-month price target?+
The 2 active firms with a live target average $3.00 for Pliant Therapeutics Inc over the next 12 months, ranging from a $3.00 high to a $3.00 low, as of Nov 19, 2026.
Is PLRX stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover PLRX?+
2 active firms have a recognized rating on Pliant Therapeutics Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PLRX?+
Among analysts who currently cover PLRX, Brian Cheng of JP Morgan has the strongest overall Quantellect track record (Rank #87). Their current call is Sell.
What is Pliant Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.40 per share (range $-0.40 – $-0.40) across 1 analysts. Full-year EPS is projected at $-1.44, rising to $-1.29 the following year.
How much revenue is Pliant Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading PLRX lately?+
As of Nov 19, 2026, 1 of 2 active firms rate PLRX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PLRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.